Equibles does not estimate personal net worth.
Get an email with a short summary when NEUROONE MEDICAL TECHNOLOGIES Corp publishes a filing, an earnings call transcript or a press release.
Get NMTC alertsDave Rosa is recorded as CEO and Board Member at NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). The newest filing on record that lists Dave Rosa as CEO and Board Member at NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) is dated March 9, 2026. The proxy statement of NEUROONE MEDICAL TECHNOLOGIES Corp reports total compensation of $1,154,436 for Dave Rosa in fiscal 2025, including a base salary of $535,428. Disclosed compensation is on record for 7 fiscal years. Dave Rosa has spoken on 17 earnings calls across 2 companies, most recently for NEUROONE MEDICAL TECHNOLOGIES Corp on August 13, 2026. Those appearances were for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) and Intuitive Surgical Inc (ISRG). NEUROONE MEDICAL TECHNOLOGIES Corp is classified in the Medical Devices industry within the Healthcare sector. Intuitive Surgical Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at NEUROONE MEDICAL TECHNOLOGIES Corp includes David Rosa (CEO and Board Member), Paul Buckman (Chairman), Christopher Volker (CFO and COO) and 7 others.
“I'd like to welcome you to our third quarter Fiscal 2026 Financial Results Conference call. Before I begin, I want to first welcome both Chris Volker, the company's chief financial officer, and David Wombeck, the company's chief business officer, as both will be presenting for the first time in their respective roles.”
“I'd like to welcome you to our second quarter fiscal 2026 financial results conference call. Product revenue for the 1RF brain ablation system in the second quarter of fiscal 2026 grew 72% year-over-year to $2.4 million, compared to $1.4 million in the second quarter of fiscal 2025.”
“I'll begin with summarizing our performance in 2025 and sharing our perspective as we enter 2026. 2025 was a strong year for Intuitive, driven by multi-specialty da Vinci procedure growth across the globe, increasing adoption of DaVinci 5, and higher utilization across our three platforms.”
“For those of you who may be new to NeuroOne, we are a medical technology company that is dedicated to transforming the diagnosis and treatment of neurological disorders.”
“For those of you who may be new to NeuroOne, we are a medical technology company that is dedicated to transforming the diagnosis and treatment of neurological disorders.”
Start not stated–present
Last confirmed March 9, 2026
Source not stated
Start not stated–present
Last confirmed March 9, 2026
Medical Devices · Healthcare
CEO, Board Member
Medical Instruments & Supplies · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $535,428 | $1,154,436 |
| 2024 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $521,856 | $1,995,745 |
| 2023 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $506,655 | $989,558 |
| 2022 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $472,436 | $1,186,410 |
| 2021 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $410,844 | $1,889,351 |
| 2020 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $403,914 | $1,122,891 |
| 2019 | NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | Chief Executive Officer and President | $392,150 | $558,166 |
